CervoMed Inc.
$5.50
-0.36%CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.2).
Valuation inputs: P/E -1.2, earnings yield N/A, momentum -0.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -41.6%, ROIC -46.5%).
Profitability stack: net margin 0.0%, ROE -41.6%, ROIC -46.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +9.0%, momentum -0.4%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
CervoMed Inc. Market vs Earnings Trajectory
Loading price and EPS data...
CervoMed Inc. Fair Value Envelope
No Revenue Data
CRVO has not reported any revenue values in the available annual periods.
CervoMed Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
CRVO has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
CRVO has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
CRVO has not reported any net profit margin values in the available annual periods.
CervoMed Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
CervoMed Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
CervoMed Inc. Street Expectations Map
Wall Street analysts project that CRVO stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 22.50, with estimates ranging from a low of 20.00 to a high of 25.00.
The consensus 1-year price target stands at 22.50, with estimates ranging from a low of 20.00 to a high of 25.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
CervoMed Inc. Insider Positioning
During the last 12 months, insiders have purchased $610K worth of CRVO shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
30.4K
240.41K
0
0.00
+240K
+$240K
9-12 Months
56.7K
369.68K
0
0.00
+370K
+$370K
Top Buyers
Gregoire Sylvie
Director, 10 Percent Owner:
$185K
Alam John J
Director, 10 Percent Owner, Officer: Ceo & President
$94K
Sabbagh Marwan
Director
$53K
Poulton Jeffrey V.
Director
$53K
Hollingsworth Jane H
Director
$53K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $610K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
CRVO has not reported any dividend yield values in the available annual periods.
crvo Dividend History
Learning Layer
Related Guides
Build conviction on CRVO by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.